Regeneron Pharmaceuticals Inc. buy SVB Securities
Start price
27.03.23
/
50%
€769.90
Target price
27.03.24
€905.83
Performance (%)
16.25%
End price
28.03.24
€895.00
Summary
This prediction ended on 28.03.24 with a price of €895.00. The BUY prediction by SVB_Securities finished with a performance of 16.25%. SVB_Securities has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.114% | 2.114% | 24.019% | -7.443% |
| iShares Core DAX® | -1,78 % | 2,48 % | 1,47 % | 58,09 % |
| iShares Nasdaq 100 | 1,52 % | 3,29 % | 33,72 % | 91,61 % |
| iShares Nikkei 225® | 1,08 % | 7,04 % | 59,26 % | 78,83 % |
| iShares S&P 500 | 0,93 % | 3,25 % | 24,73 % | 70,00 % |
Comments by SVB_Securities for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at SVB Securities from a "market perform" rating to an "outperform" rating. They now have a $976.00 price target on the stock, up previously from $834.00.
Ratings data for REGN provided by MarketBeat
In the thread Trading Regeneron Pharmaceuticals Inc.
Die von SVB_Securities gewählte maximale Laufzeit wurde überschritten